CAR T-cell therapy is an exciting second-line option for patients living with relapsed multiple myeloma. In this presentation, Dr. Ahmed reviews each step in the CAR T process and discusses a number of studies that support its use. Potential side effects are reviewed, and exciting future trends are discussed.

La terapia de células CAR T es una nueva opción de tratamiento para pacientes con leucemia linfoblástica aguda, algunos linfomas y mieloma múltiple que no han respondido a terapias anteriores. Esta presentación describe cómo funciona la terapia de células CAR T, sus riesgos y efectos secundarios, y cómo estos pueden manejarse de manera efectiva.

The age of patients undergoing a stem cell transplant or CAR T-cell therapy is increasing, but older patients are often not as fit as younger adults. Transplant and CAR T-cell therapies can be modified to increase the likelihood of success for old adults.

CAR T-cell therapy is a new treatment option for patients with acute lymphoblastic leukemia, some lymphomas, and multiple myeloma that have not responded to prior therapies. This presentation describes how CAR T-cell therapy works, its risks and side effects, and how these may be effectively managed.